Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $72.6 million.

  • vTv Therapeutics' Net Cash Flow rose 193519.6% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.9 million, marking a year-over-year increase of 7080.07%. This contributed to the annual value of $27.3 million for FY2024, which is 111865.67% up from last year.
  • Latest data reveals that vTv Therapeutics reported Net Cash Flow of $72.6 million as of Q3 2025, which was up 193519.6% from -$5.1 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Net Cash Flow high stood at $72.6 million for Q3 2025, and its period low was -$6.7 million during Q2 2024.
  • Its 5-year average for Net Cash Flow is $4.9 million, with a median of -$2.5 million in 2022.
  • As far as peak fluctuations go, vTv Therapeutics' Net Cash Flow plummeted by 49942.05% in 2024, and later soared by 193519.6% in 2025.
  • Quarter analysis of 5 years shows vTv Therapeutics' Net Cash Flow stood at -$6.2 million in 2021, then surged by 47.76% to -$3.2 million in 2022, then surged by 137.6% to $1.2 million in 2023, then plummeted by 499.42% to -$4.8 million in 2024, then skyrocketed by 1604.29% to $72.6 million in 2025.
  • Its Net Cash Flow was $72.6 million in Q3 2025, compared to -$5.1 million in Q2 2025 and -$5.7 million in Q1 2025.